MGMT, O-6-methylguanine-DNA methyltransferase, 4255

N. diseases: 444; N. variants: 24
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0206726
Disease: gliosarcoma
gliosarcoma
0.360 PosttranslationalModification disease BEFREE Gross-total resection also improved survival, and there was a trend toward increased survival with MGMT promoter methylation in GS. 28621623 2018
CUI: C0206726
Disease: gliosarcoma
gliosarcoma
0.360 Biomarker disease BEFREE In conclusion, this study demonstrates that concomitant TMZ together with radiation therapy increases GSM-patient survival independent of MGMT promoter methylation. 27025857 2016
CUI: C0206726
Disease: gliosarcoma
gliosarcoma
0.360 PosttranslationalModification disease BEFREE The O6-methylguanine-DNA methyltransferase promoter methylation studies were significantly more frequent in the GBMs than GSMs (80.1% vs. 44.7%, P < 0.001). 26725096 2016
CUI: C0206726
Disease: gliosarcoma
gliosarcoma
0.360 PosttranslationalModification disease BEFREE A study of clinico-pathological parameters and O⁶-methylguanine DNA methyltransferase (MGMT) promoter methylation status in the prognostication of gliosarcoma. 22380407 2012
CUI: C0206726
Disease: gliosarcoma
gliosarcoma
0.360 Biomarker disease ORPHANET A study of clinico-pathological parameters and O⁶-methylguanine DNA methyltransferase (MGMT) promoter methylation status in the prognostication of gliosarcoma. 22380407 2012
CUI: C0206726
Disease: gliosarcoma
gliosarcoma
0.360 GeneticVariation disease BEFREE A case of primary gliosarcoma with both IDH1 mutation and MGMT methylation had a focal oligodendroglial component.No IDH2 mutation was found. 22270848 2012
CUI: C0206726
Disease: gliosarcoma
gliosarcoma
0.360 Biomarker disease ORPHANET In the present study, we determined the status of MGMT using methylation-specific polymerase chain reaction (PCR) and immunohistochemistry on paraffin-embedded specimens in 12 human gliosarcomas, and these results were then related to overall survival (OS) and response to alkylating agents. 20556478 2011
CUI: C0206726
Disease: gliosarcoma
gliosarcoma
0.360 PosttranslationalModification disease BEFREE In the present study, we determined the status of MGMT using methylation-specific polymerase chain reaction (PCR) and immunohistochemistry on paraffin-embedded specimens in 12 human gliosarcomas, and these results were then related to overall survival (OS) and response to alkylating agents. 20556478 2011